Vertex Announces Plans to Enroll Additional Treatment Arm in Ongoing Phase 2 Combination Study of Telaprevir and VX-222
for the Treatment of People with
Hepatitis C
-New treatment arm to evaluate all oral, triple combination regimen of telaprevir, VX-222, and ribavirin-
CAMBRIDGE, Mass., Nov 10, 2010 (BUSINESS WIRE) -- Vertex Pharmaceuticals Incorporated /quotes/comstock/15*!vrtx/quotes/nls/vrtx (VRTX 33.47, -0.63, -1.